SPHRY (SPHRY) Stock Price & Analysis
SPHRY (SPHRY) rose 1.59% to USD 5.1 as of June 10, 2026 at 03:48 UTC, according to Nexqual real-time market data.
SPHRY last closed at USD 5.02; the session ranged USD 5.1–5.1 on volume of 500 shares. Market capitalization is $225.63M, with a 52-week range of USD 0.55–5.7 (OQX). Source: Nexqual, June 10, 2026 at 03:48 UTC.
Key Statistics (as of June 10, 2026 at 03:48 UTC)
| Price | USD 5.1 |
|---|---|
| Change | ▲ 1.59% (up) |
| Previous Close | USD 5.02 |
| Open | USD 5.1 |
| Day Range | USD 5.1 – 5.1 |
| 52-Week Range | USD 0.55 – 5.7 |
| Volume | 500 shares |
| Market Cap | $225.63M |
| Exchange | OQX |
Technical Analysis (SPHRY)
Nexqual's technical model rates SPHRY "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 03:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.62 (neutral) |
| vs SMA50 | Above (USD 4.6) |
| MACD | 0.12 (positive) |
Analyst Ratings (SPHRY)
Wall Street analysts rate SPHRY "None", per Nexqual as of June 10, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|
Earnings (SPHRY)
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financials & Fundamentals (SPHRY)
| Total Revenue | $14.58M |
|---|---|
| Revenue Growth (YoY) | +359.60% |
| Gross Margin | +29.59% |
| Operating Margin | +12.26% |
| Profit Margin | -22.16% |
| ROE | -14.47% |
| Debt / Equity | 3.68 |
| Current Ratio | 5.26 |
| Total Cash | $18.25M |
| Total Debt | $790,000 |
| Free Cash Flow | $-612,375 |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financial Health Score (SPHRY)
Nexqual rates SPHRY's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:48 UTC.
| Growth | Strong — Revenue +360% YoY (latest Q) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$852K |
| Efficiency | Critical — ROE -14%, ROA -7.2% |
Ownership (SPHRY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 42.09M |
| Float | 31.97M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Leadership (SPHRY)
SPHRY is led by Cheryl Maley B.Sc. (age 57), CEO, MD & Director, per Nexqual as of June 10, 2026 at 03:48 UTC.
| CEO, MD & Director | Cheryl Maley B.Sc. (age 57) |
|---|---|
| CFO & Company Secretary | Justin Cahill |
| Director of People & Culture | Miranda Sowden |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPHRF | STARPHARMA HOLDINGS LIMITED | USD 0.35 | ▼ 35.19% |
| CLVLY | Clinuvel Pharmaceuticals Ltd. | USD 6.36 | ▼ 3.64% |
| SNPHY | Santen Pharmaceutical Co., Ltd. | USD 12.2 | ▲ 3.83% |
| SPL.AX | STARPHARMA FPO [SPL] | AUD 0.69 | ▼ 9.27% |
| ACCL | Acco Group Holdings Limited | USD 1.52 | ▼ 1.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:48 UTC. This page is informational and not investment advice.